• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Immunol. Author manuscript; available in PMC Aug 30, 2010.
Published in final edited form as:
PMCID: PMC2929904
NIHMSID: NIHMS212010

IL-15 treatment during acute SIV infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses

Abstract

In this study, we examined the effect of in vivo treatment of acutely SIV infected Mamu-A*01+ rhesus macaques with interleukin 15 (IL-15). IL-15 treatment during acute infection increased viral set point by 3 logs and accelerated the development of simian AIDS in 2 out of 6 animals with one developing early minimal lesion SIV meningoencephalitis. Although IL-15 induced 2–3 fold increase in SIV-specific CD8+ T cell and NK cell numbers at peak viremia and reduced lymph node (LN) SIV-infected cells this had no impact on peak viremia and did not lower viral set point. At viral set point however activated SIV-specific CD8+ T cells and NK cells were reduced in the blood of IL-15 treated animals and LN SIV-infected cells were increased. Week 30 LN from IL-15 treated animals had significantly increased Gag-specific CD8+ T cell numbers, whereas total cell, lymphocyte, and CD4+ T cell numbers were reduced. IL-15 treatment significantly reduced anti-SIV antibody concentrations at week 3 and viral set point. IL-15 increased Ki-67+CD4+ T cells at week 1 of treatment and reduced blood CCR5+ and CD45RA-CD62L− CD4+ T cells. The frequency of day 7 Ki-67+CD4+ T cells strongly correlated with viral set point. These findings suggest that CD4+ T cell activation during acute infection determines subsequent viral set-point and IL-15 treatment by increasing such activation elevates viral set-point. Finally, IL-15 treated acutely SIV infected primates may serve as a useful model to investigate the poorly understood mechanisms that control viral set point and disease progression in HIV infection.

Keywords: Immunodeficiency Diseases, Cytokines, T Cells, Cytotoxic, Apoptosis, Memory

Introduction

Increasing function and effectiveness of CD8+ T cells is one of the major goals in the fight against viral infections such as HIV infections. Although studies indicated the important role of virus-specific CD8+ T cells in HIV and SIV infection (15), these cytotoxic T cells are unable to control viral replication and progression of HIV infection. In recent years, intrinsic defects were suggested for HIV-(6, 7) and SIV-specific CD8+ T cells (8) which result in reduced survival and skewed differentiation of effector memory virus-specific CD8+ T cells. Improving the survival and function of these virus-specific CD8+ T cells by cytokine therapy may therefore increase viral control. IL-15 is a proinflammatory cytokine produced by variety of cells including macrophages/monocytes, dendritic cells, and bone marrow stromal cells (912) and binds to the IL-15 receptor, composed of the specific IL-15Rα chain expressed on lymphoid, myeloid, non-hematopoietic cells including macrophages and monocytes, NK cells and CD8+ T cells (13, 14), the IL-2Rβ chain and the γc chain. Trans-presentation of IL-15 has been shown to be a major signaling mechanism (1517) although this may not be true for all cell types (18). Several studies have shown IL-15's ability to enhance the activation, function and proliferation of NK cells and CD8+ T cells (1826), and to function as a chemoattractant for the homing of lymphocytes to peripheral lymph nodes (LN) and inflamed tissue either directly (11, 27, 28) or indirectly by inducing IL-8 and MCP-1 by monocytes (29). IL-15 overexpression suppresses progression to murine acquired immunodeficiency syndrome in mice infected with LP-BM5 murine leukemia virus (30) and can act as a plasmid adjuvant (3133). In vitro IL-15 enhances survival, inhibits CD95-induced apoptosis and augments effector function of HIV-specific CD8+ T cells (34, 35). Furthermore, IL-15 stimulates expansion of HIV-specific CD8+ T cells (36, 37), and restores NK cytotoxicity and deficient IL-12 production by PBMC from HIV infected individuals (19).

The above effects of IL-15 have suggested its use as an immune augmenter in HIV infection. In previous studies we have shown that high dose (100μg/kgr) IL-15 treatment of chronically infected cynomolgus macaques results in a 3 fold expansion of CD8+ T cells and NK cells. Others have shown that low dose (10μg/kgr) IL-15 treatment of chronically infected animals may restore the CD4+ T cell compartment but only when viral replication is controlled by antiretrovirals (38). These studies led us to investigate the effect of IL-15 treatment during acute SIV infection in Mamu-A*01+ rhesus macaques. Our data show that IL-15 treatment increases viral set point by 3 logs and leads to accelerated disease progression to simian AIDS in 2 out of 6 animals with one developing SIV meningoencephalitis. IL-15 induced 2–3 fold increases in SIV-specific CD8+ T cell and NK cells during the acute infection without effect on viremia. Although increased viral set point was accompanied by reduced blood activated SIV-specific CD8+ T cells and NK cells, LN numbers of SIV-specific CD8+ T cells were increased whereas LN NK cell numbers were not affected. Expression of Ki-67 in CD4+ T cells at day 7 post infection was positively correlated with viral load at day 84. These findings suggest that IL-15 may be altering the course of the disease by enhancing the proliferation of CD4+ T cells early during infection and promoting their migration into tissue hence increasing the target pool of SIV infection. Thus the level of CD4+ T cell activation during acute infection may determine the viral set point months later. Finally, our findings also indicate that IL-15 treatment of acutely SIV infected non-human primates may prove useful as an animal model to elucidate what controls viral set point.

Material and Method

Animals

The 12 Mamu-A*01+ male Indian rhesus macaques (Macaca mulatta) included in this study were housed at the Bioqual animal facility according to standards and guidelines as set forth in Animal Welfare Act and “The Guide for the Care and Use of Laboratory Animals,” (ILAR, 1996), and according to animal care standards deemed acceptable by the Association for the Assessment and Accreditation of Laboratory Animal Care-International (AAALAC). All experiments were performed following institutional animal care and use committee (IACUC) approval. The animals were inoculated intravenously with 100 ID50 SIVmac251 and either treated with 100 μg/kg bodyweight rhesus macaque IL-15 or with saline (control) subcutaneously twice weekly for 4 weeks. SIV RNA levels were measured using a quantitative TaqMan RNA RT-PCR assay (sensitivity of 200 SIV RNA copies/ml blood, Applied Biosystems, Foster City, CA) (39). Recombinant rhesus macaque IL-15 was provided through the NCRR funded Resource for Nonhuman Primate Immune Reagents (40).

Flow cytometry

Blood of animals was processed within 6 hours after blood draw. Freshly density centrifugation isolated PBMC (Percoll, 1.075 g/ml, Amersham Biosciences, Uppsala, Sweden) were stained ex vivo or used for apoptosis, cytotoxicity and cytokine production assays. Mamu-A*01-β2-microglobulin tetramers were loaded with SIV Gag 181–189 CM9 (CTPYDINQM) or SIV Tat SL8 28–35 (STPESANL) peptide (41). The following rhesus macaque cross-reacting anti-human antibodies were used: anti-CD3 (clone SP34), anti-CD4 (L200), anti-CD8 (3B4), anti-CD20 (2H7), anti-CD25 (M-A251), anti-CD69 (FN50), anti-CD45RA (5H9), anti-CD62L (SK11), anti-HLA-DR (L243/G46-6), anti-Ki-67 (B56), anti-IL-2 (MQ1-17H12), anti-IFN-γ (4S.B3), anti-TNFα (Mab11), anti-IL-10 (JES3-9D7), anti-CD195 (CCR5, 3A9), and Annexin-V (BD Biosciences, San Jose, CA; eBioscience, San Diego, CA; Invitrogen, Carlsbad, CA; SouthernBiotech, Birmingham, AL). PBMC were stained with up to 10 different antibodies in HBSS (Cellgro, Herndon, VA), 3% heat inactivated horse serum (Invitrogen), 0.02% NaN3 for 30 min on ice, washed x2, and fixed with 1% paraformaldehyde. For intracellular staining, PBMC were first surface stained, fixed and permeabilized (cytofix-cytoperm, BD Biosciences), incubated with the antibodies and isotype controls and fixed with 1% paraformaldehyde. Lymphocytes were isolated from inguinal LN by incubation of minced LN tissue in digestion media (0.15mg/ml DNase (Roche Applied Science, Indianapolis, IN), 3 mg/ml Collagenase A (Roche Applied Science) for 2 hours at 37°C followed by red blood lysis (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.2) for 5 minutes at room temperature. Samples were collected on a FACSCalibur and FACSAria (BD Biosciences) and analyzed using FlowJo software (TreeStar, San Carlos, CA).

Cytokine stimulation

Freshly isolated PBMC were stimulated for 6 hours with SIV Gag 181–189 CM9 (CTPYDINQM) peptide or SIV Tat SL8 28–35 (STPESANL) peptide at a concentration of 10 μg/ml in the presence of 1 μg/ml anti-CD28 and anti-CD49e antibody (eBioscience) with Brefeldin A (10μg/ml, BD Biosciences) added for the last 4.5 h. Surface and intracellular staining was performed directly afterwards. Background (cells cultivated without peptide) was subtracted from the peptide-stimulated samples and absolute cell number of cytokine producing cells was calculated.

Apoptosis

For spontaneous apoptosis, freshly isolated PBMC from SIV-infected untreated and IL-15 treated animals were cultured in RPMI 1640/10% heat-inactivated FBS/2 mM L-Glutamine/100 U/ml Penicillin/100 μg/ml Streptomycin-sulfate (Cellgro). For CD95-induced apoptosis, PBMC were incubated in the presence of 10 ng/ml soluble FasL (Axxora, San Diego, CA) and 1 μg/ml enhancer (Axxora). Cells were harvested after 14h incubation and stained for flow cytometry analysis.

Cytotoxicity assay

To measure cytotoxicity of NK cells, freshly isolated PBMC were incubated at effector/target ratios as indicated with 5×104 Na251CrO4 (PerkinElmer, Boston, MA) radiolabeled K562 target cells in 96-well U-bottom plates for 5 h at 37 °C. 30 μl of supernatants were transferred to 96-well LumaPlates (Packard BioScience Company, Meriden, CT) and counted in a TopCount microplate scintillation counter (Packard BioScience Company). Specific cytotoxicity was determined using the formula: (cpm experimental release - cpm spontaneous release)(cpm maximal release - cpm spontaneous release)×100

SIV-specific antibody ELISA

Total SIV-specific antibodies (IgM and IgG) were measured in plasma of untreated and IL-15 treated acutely SIV-infected rhesus macaques using the Genetic Systems HIV-2 EIA (BIO-RAD, Redmond WA) according to the manufacturer's instructions.

Brain histology

For each animal detailed gross and microscopic neuropathological evaluation was performed. Brain specimens were fixed in formalin. Multiple representative sections from the cerebral neocortex and corresponding portions of hemispheric white matter of the frontal, parietal temporal and occipital lobes, hippocampus, basal ganglia, diencephalic structures (thalamus, hypothalamus, subthalamus), brain stem and cerebellum were analyzed (20 paraffin/animal). Histological sections were stained with hematoxylin and eosin and luxol-fast-blue/cresyl violet and evaluated. The extent and distribution of inflammatory lesions was analyzed and rated after Boche et al.(42) as follows: (±) rare, scant/sparse, (+) frequent, scant/sparse, (++) frequent and marked.

SIV-specific in situ hybridization

Tissues (rectum pinch biopsy samples, inguinal LN) were fixed with formalin, embedded in paraffin and were assayed for SIV viral RNA expression by in situ hybridization as previously described (43). Briefly, the tissue sections were hybridized overnight at 50°C with either sense or anti-sense SIVmac239 digoxigenin-UTP labeled riboprobe, blocked with 3% normal sheep and horse serum in 0.1M Tris, pH 7.4 and incubated with sheep anti-digoxigenin-alkaline phosphatase (Roche Molecular Biochemicals) and NBT/BCIP (Vector Labs).

Statistical analysis

Statistical analysis was performed using a 2-way ANOVA when data was normally distributed or could be transformed to attain that distribution. Otherwise a series of non-parametric tests (Mann-Whitney U) between the groups at each time was used.

Results

IL-15 treatment did not induce any severe side effects

To examine whether IL-15 treatment induced clinical side effects, animals were tested weekly for several parameters. Glucose, blood urea nitrogen, creatinine, total protein, albumin, globulin, total bilirubin, alkaline phosphatase, sodium, potassium, triglyceride lipid and amylase concentration showed no differences when untreated and IL-15 treated animals were compared. The concentration of phosphorus was significantly reduced in the blood with IL-15 treatment at week 4 and 6, with no differences at later time points (data not shown), whereas the concentration of calcium was comparable between untreated and IL-15 treatment. We also observed a transient decrease in the amount of alanine aminotransferase at week 3 and week 4 in the IL-15 treated animals. Additionally, hematological measurements (white blood cell numbers, red blood cell numbers, platelets, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet numbers) were also performed weekly, with no differences observed between untreated and IL-15 treated animals. IL-15 treatment was therefore well tolerated by the animals and did not lead to toxic side effects, which is in agreement with the results of our previous study in which we treated chronically SIV-infected cynomolgus macaques (40).

IL-15 treatment during acute infection increased viral set point

Viral load was followed in all 12 SIV-infected animals up to week 20. IL-15-treated animals had a slightly increased plasma viral load initially with 5.7±3.6×106 SIV RNA molecules/ml at day 7 and 20±5.9×106 SIV RNA molecules/ml at day 14 compared to untreated animals (2.6±1.4×106 SIV RNA molecules/ml at day 7 and 10±1.5×106 SIV RNA molecules/ml at day 14) (Figure 1). After week 3, viral load in the untreated animals slowly decreased whereas in IL-15 treated animals, viral load remained high. This resulted in a 1 log higher viral load in IL-15 treated animals at week 6 (4.4±3.1×106 SIV RNA molecules/ml for IL-15 treated animals and 0.18±3.1×106 SIV RNA molecules/ml for untreated animals, p=0.042) and a 3 log higher viral load at week 20 (42±28×106 SIV RNA molecules/ml for IL-15 treated animals and 2.4±0.9×104 SIV RNA molecules/ml for untreated animals, p=0.017) (Figure 1).

Figure 1
IL-15 increases viral set point

Increased SIV-specific CD8+ T cells during IL-15 treatment is followed by decreased activated SIV-specific CD8+ T cells at viral set point

IL-15-treated animals at week 2 post-infection had a 2.3 fold increase in Gag- and a 3 fold increase in Tat-specific CD8+ T cells (p=0.044) compared to untreated animals (Figure 2A). However, at all later time points virus-specific CD8+ T cell numbers were comparable between IL-15 treated and untreated animals. In IL-15 treated animals we observed 1.6 fold more CD8+ T cells at week 2 (Figure 2B). After cessation of IL-15, the CD8+ T cells numbers were comparable between IL-15 treated and untreated animals throughout the study. No differences were found in the absolute CD4+ T cell and CD20+ B cell numbers (Figure 2B).

Figure 2
IL-15 treatment alters SIV-specific CD8+ T cell and NK cell numbers

To determine whether IL-15 treatment altered activation of cells, we analyzed expression of the activation markers CD69, CD25, and HLA-DR. IL-15 treatment reduced the frequency of HLA-DR+ Gag-specific CD8+ T cells in the peripheral blood compared to untreated animals beginning at week 6 (untreated animals: 23±3.4%, IL-15 treated animals: 8.2±1.3%; p<0.05) (Figure 3A). A similar decrease was observed for total CD8+ T cells (Figure 3A). IL-15 treatment did not alter the expression of CD69, CD25, and HLA-DR on CD4+ T cells and CD20+ B cells (data not shown).

Figure 3
IL-15 treatment decreases percentage of HLA-DR+ CD8+ T cells and CCR5+ CD4+ T cells in peripheral blood

Reduced CD3-CD8+ NK cells during viral set point in IL-15 treated animals

An increase in cell numbers due to IL-15 treatment was also found for CD3-CD8+ NK cells with a 2.3 fold increase at week 1 (p=0.049) (Figure 2B). However, although IL-15 was given until week 4, the absolute NK cell numbers were not different for IL-15 treated and untreated animals from week 2 to 4. After week 4, IL-15 treated animals had reduced NK cell numbers compared to untreated animals with up to significantly 67% reduction at week 16 (p=0.02) (Figure 2B). However, as mentioned below, week 30 LN from IL-15 treated animals showed no decrease in CD3-CD8+ NK cells suggesting that CD3-CD8+ NK cells are specifically reduced from circulation (Figure 3D).

IL-15-treated SIV infected animals have decreased CCR5+ and CD45RA-CD62L− CD4+ T cells in peripheral blood

We next analyzed the expression of CCR5, which is upregulated by IL-15 (44). Although during the first 4 weeks, no differences were found, at later time points the percentage of CCR5+ CD4+ T cells in the IL-15 treated animals decreased to less than 1% whereas in the untreated animals more than 5% CCR5+ CD4+ T cells were found between week 6 and 12 (p=0.049) (Figure 3B). CCR5 expression on Gag-specific CD8+ T cells, total CD8+ T cells, NK cells, and monocytes was comparable between untreated and IL-15 treated animals (data not shown).

Using CD45RA and CD62L we also analyzed memory cell distribution of CD4+ T cells which did not differ when untreated and treated animals were compared during the initial IL-15 treatment period. Thereafter, however, a 50% reduction of CD45RA-CD62L− CD4+ T cells were found in IL-15 treated animals (week 6, 12±2% for treated and 23±3% for untreated animals (p=0.016); week 20: 10±1% for treated and 25±6% for untreated animals (p=0.049)). On the other hand, CD45RA-CD62L+ cells were increased in IL-15 treated animals (week 6: 63±8%, week 20 56±4%) compared to untreated animals (week 6: 51±9%, week 20: 38±3%) (Figure 3C).

Memory cell distribution and spontaneous and CD95-induced apoptosis was also examined in SIV-specific CD8+ T cells as reduced survival and skewed memory phenotype was described as intrinsic defects for HIV-specific CD8+ T cells. No difference was found in the distribution of memory subpopulations of Gag- and Tat-specific CD8+ T cells and total CD8+ T cells when IL-15 treated and untreated animals were compared (data not shown). Spontaneous and CD95-induced apoptosis was comparable in SIV-specific CD8+ T cells, total CD8+ T cells and CD4+ T cells when PBMC from untreated and IL-15 treated animals were compared (data not shown).

Gag-specific CD8+ T cell number are increased in LN of IL-15 treated chronically SIV infected rhesus macaques

Biopsies of inguinal LN were collected 30 weeks after SIV infection and IL-15 treatment. Viral loads were 25,387±17,994 SIV RNA molecules/ml blood in the IL-15 treated animals (n=3) and 8440±4210 SIV RNA molecules/ml blood in the untreated animals (n=3). The LN of IL-15 treated animals were significantly smaller (169±49 mg) than the ones from untreated animals (367±51 mg) (p<0.05). Accordingly, total cell, lymphocyte and CD4+ T cell numbers per LN were significantly reduced in IL-15 treated animals. Despite this overall reduction the percentage (data not shown) and absolute cell numbers of Gag-specific CD8+ T cells were increased in the IL-15 treated animals compared to untreated animals (p=0.049) (Figure 3D). No significant differences in total CD8+ T cell, CD3-CD8+ NK cell or CD20+ B cell numbers were observed between LN from untreated and IL-15 treated animals (Figure 3D).

Percentage of day 7 Ki-67+ CD4+ T cell correlates positively with day 84 viral replication

We next examined whether viral load at day 14 (peak) and day 84 (viral set point) correlated with activation and proliferation of CD4+ T cells and Gag-specific CD8+ T cells at day 7, 14, and 84. We observed a significant increase in the percentage of Ki-67+ CD4+ T cells at day 7 post infection in the IL-15 treated animals compared with the untreated animals (Figure 4A). When the correlation was examined between the percentage of Ki-67+CD4+ T cells on day 7 post infection and viral load, a positive correlation was observed for day 14 viral load (R2 = 0.38, p=0.03) and day 84 viral load (R2 = 0.78, p=0.002) (Figure 4B). However, we did not see any significant correlation when percentage of day 14 and 84 Ki-67+CD4+ T cells were analyzed, which is in agreement with our observations that there was no difference between the percentage of Ki-67+CD4+ T cells in untreated and IL-15 treated animals at these later time points. A positive correlation was also seen when the absolute cell numbers of Ki-67+CD4+ T cells at day 7 and viral replication at day 14 (R2:0.72, p=0.03) and day 84 (R2:0.68, p=0.04) were compared. No correlation was found between percentage and absolute cell numbers of CD25+CD4+ T cells and viral load. Whereas no correlation was found between percentage of HLA-DR+CD4+ T cells and viral load, absolute HLA-DR+CD4+ T cells on day 7 correlated positively with viral load at day 14 (R2: 0.82, p=0.01) and day 84 (R2: 0.73, p=0.03). When we examined the correlation between absolute SIV-specific CD8+ T cell numbers and viral replication, we found no significant correlation. The same was true for absolute cell numbers of CD25+, HLA-DR+ and Ki-67+ SIV-specific CD8+ T cells and viral load. However, the percentage of day 84 CD25+ and Ki-67+ SIV-specific CD8+ T cells correlated positively with viral load (data not shown), indicating that increased viral replication maintains activation of virus-specific CD8+ T cells.

Figure 4
Ki-67 expression is increased during IL-15 treatment in T cells and NK cells and Ki-67+ CD4+ T cells correlate with viral set point

IL-15 induced increased lymphocyte proliferation in SIV-infected animals

Next we examined whether the increased cell numbers were due to proliferation of these cells by analyzing the expression of Ki-67. No difference in Ki-67 expression of SIV-specific CD8+ T cells was observed in IL-15 treated animals (Figure 4A). IL-15 treated animals had a significant increase in frequency of Ki-67+ total CD8+ T cells (59±5.3%) compared to the untreated group (13±2.1%) at week 1 (p=0.004), but lower Ki-67+ CD8+ T cells at weeks 6 and 8 (Figure 4A). Similarly, the IL-15 treated group had significantly more Ki-67+ NK cells at week 1 (88±2%) compared to the untreated group (26±6%) (p=0.004) and significantly less Ki-67+ NK cells in IL-15 treated animals at weeks 6 and 8 (Figure 4A). Although absolute CD4+ T cell numbers did not differ between IL-15 treated and untreated animals (Figure 2B), the IL-15 treated group had a 2 fold increase of Ki-67+ CD4+ T cells at week 1 (21±2.5%) compared to the untreated animals (10±1.4%) (p=0.015) (Figure 4A). At weeks 6 and 8, increased Ki-67+ CD4+ T cells were observed in the untreated but not in the IL-15 treated animals.

In vivo IL-15 treatment did not enhance NK cytotoxicity and cytokine production by SIV-specific CD8+ T cells

The central question of this study was whether IL-15 could enhance the innate and adaptive immune response against SIV infection. We therefore examined cytotoxicity of NK cells and peptide-mediated cytokine secretion of CD8+ T cells in untreated and IL-15 treated animals. IL-15 treatment increased the absolute numbers of TNF-α and IFN-γ producing CD8+ T cells stimulated with the Gag-peptide at week 2 (Figure 5A). However, because the absolute Gag-specific CD8+ T cell number was higher in the IL-15 treated animals, this did not result in an increase in the percentage Gag-peptide responding cells through IL-15 treatment. The same was seen when CD8+ T cells were stimulated with the Tat peptide although only an increase in IFN-γ producing CD8+ T cells but not in TNF-α CD8+ T cells was observed at week 2 (Figure 5A and data not shown). No difference was found in IL-2 and IL-10 production by SIV-specific CD8+ T cells between untreated and IL-15 treated animals (data not shown). Finally, NK cell cytotoxicity did not differ between three IL-15 treated and three untreated animals analyzed at week 0 pre-infection and week 1, 2, 3, 4, and 6 post-infection (Figure 5B).

Figure 5
No enhanced effector function of CD8+ T cells and NK cells in IL-15 treated animals

IL-15 treatment reduces SIV-infected cells in LN at peak viremia but increases them at viral set point

Inguinal LN and rectal biopsies were collected from three IL-15 treated and three untreated animals and analyzed for SIV infection by in situ hybridization. No statistical difference in the number of SIV-infected cells was found in rectal biopsies when untreated and IL-15 treated animals were compared (week 1: 1.51±1.39 cells/mm2 and 1.44±2.04 cells/mm2, week 8: 0.09±0.16 cells/mm2 and 0.08±0.13 cells/mm2 for untreated and IL-15 treated animals, respectively). In LN biopsies significantly less SIV infected cells were found at week 2 (peak viremia) in the IL-15 treated (1.6±0.8 SIV-infected cells/mm2 tissue) compared to the untreated animals (7.8±1.5 SIV-infected cells/mm2 tissue) (p=0.021) (Figure 5C). Although no statistical differences were observed at later time points it appeared that IL-15 treatment increased the number of SIV-infected cells in LN. When infected macrophages and infected lymphocytes were estimated based on morphology, no difference in numbers of SIV-infected macrophages and lymphocytes were found between untreated and IL-15-treated groups.

Anti-SIV antibodies are decreased in IL-15 treated animals

To examine whether IL-15 treatment altered B cell function we analyzed anti-SIV antibodies in the plasma of untreated or IL-15 treated animals at week 3 (early infection) and at week 16 (viral set point). Significant less anti-SIV antibodies were found at both time points in the IL-15 treated animal group compared to the untreated one (week 3: 0.05±0.03 arbitrary units (AU) versus 0.22±0.06 AU, p=0.046 and week 16: 3.3±2 AU versus 16±5.2 AU, p=0.025, for IL-15 treated and untreated animals, respectively) (Figure 5D). The decrease in antibody production was however not accompanied by a change in B cell numbers either in peripheral blood (figure 2B) or in LN (figures 3D). To further examine whether the reduced anti-SIV antibody concentration could result in increased viral load, correlations between antibody and viral replication were analyzed at week 3 and week 16. No correlation was observed for week 3 antibody concentration and viral replication, however, a inverse correlation was found for week 16 antibody concentration and viral replication (R2: 0.34, p=0.045). If IL-15-induced changes in antibody production are associated with CD4 activation/proliferation, a correlation between Ki-67+CD4+ T cells and amount of antibody should be observed. Indeed, we found an inverse correlation between the percentage of Ki-67+CD4+ T cells at week 1 and the amount of antibodies at week 3 (R2: 0.68, p=0.001) and 16 (R2:0.45, p=0.017).

IL-15 accelerated disease progression and induced meningoencephalitis

The increase in viral load indicated already that IL-15 treatment during acute infection may increase the normally slow progression of SIV infection in Mamu-A*01+ rhesus macaques (45, 46). We therefore followed the animals up to week 30. Two out of the 6 IL-15 treated animals had to be euthanized at week 25 and week 26, respectively, due to simian AIDS with a plasma viral load of 103×106 SIV RNA molecules/ml and 53×106 SIV RNA molecules/ml, respectively. The other 4 IL-15 treated animals are alive at week 30 with plasma viral load of 53±51×104 SIV RNA molecules/ml whereas the six untreated animals had a viral load of 7.4±6.6×104 SIV RNA molecules/ml blood.

One of the two animals euthanized due to simian AIDS showed clinical signs of central nervous system (CNS) involvement such as signs of visual impairment. We therefore examined the brain to analyze whether IL-15 treatment not only accelerates progression to AIDS but also leads to early involvement of the brain. Gross examination of the brain of the two euthanized animals was essentially unremarkable. One of two animals showed a mild, focal meningoencephalitis characterized by rare, discrete, randomly distributed and scant inflammatory infiltrates -consisting predominantly of monocytes/macrophages, to a lesser extent lymphocytes- involving the cerebellar and cerebral leptomeninges (Figure 6A–C). Neither substantial meningitis nor leptomeningeal thickening were observed. Scant perivascular mononuclear inflammatory cell infiltrates were detected only in the cortex (not shown). In addition, patchy microglial nodules were detected focally in the superficial/subpial cortical gray matter together with mild to moderate subpial gliosis (Table I, Figure 6D). No perivascular syncytial/multinucleated giant cells, microglial nodules, endothelial hypertrophy were identified. The cerebral white matter was devoid of myelin pallor and/or vacuolar changes. Collectively, these changes are consistent with early, minimal CNS SIV-associated changes in the context of `early encephalitis'.

Figure 6
IL-15 treatment induced meningoencephalitis
Table I
Histological findings in SIV-infected rhesus macaque with simian AIDS

Discussion

Several in vitro and in vivo studies in recent years have indicated that cytokine therapy may be a promising adjunctive therapeutical treatment for HIV infection. Candidate cytokines that have been tested in animals are IL-7 (47, 48), IL-12 (49), IL-2 (50, 51) and IL-15 (38, 40, 51). The effect of such cytokine treatment on acute infection however is unexplored. By providing a cytokine adjuvant during acute infection one can envision changing the whole dynamics of host virus interaction leading to either better control or accelerating disease and thus allowing us to understand better the mechanisms that control viral loads. One of the most promising cytokine is IL-15, which was shown in in vitro studies to increase survival and effector function of HIV (34) and SIV-specific CD8+ T cells (8). This study was therefore performed to examine whether in vivo IL-15 treatment during acute SIV infection of rhesus macaques could enhance the immune control of viral replication. We found however that IL-15 treatment during acute infection increased the viral set point in animals and accelerated disease progression in some animals.

The increased viral set point of animals treated with IL-15 could be due to a direct effect of IL-15 on viral replication. In vitro IL-15 has either a marginal effect (19, 52, 53) or no effect (54, 55) on replication of HIV in naturally infected PBMC. In PHA stimulated freshly HIV infected PBMC however IL-15 can induce various amounts of HIV replication that differ from study to study (44, 5356). This suggests that the effect of IL-15 on viral replication may depend on the activation status of the cells. In agreement with this, we have observed an increase in viral load in our present study treating acutely SIV infected monkeys when intense immune activation is occurring. In contrast, earlier studies showed that IL-15 treatment of chronically SIV-infected animals did not increase viral set point (38, 40). An important difference in acute infection may be the presence of high amounts of IL-2, as IL-2 and IL-15 synergize to increase viral replication (54). Although no IL-2 mRNA was found in peripheral blood during acute HIV infection, LN biopsies have high amounts of IL-2 mRNA (57). Thus during acute infection endogenous IL-2 and exogenous IL-15 could synergize leading to increased viral replication. Although this could be happening in our current study of IL-15 treatment, the fact that no difference in peak viral loads was seen when animals were still being treated with IL-15, would argue against this as a mechanism of increased viral set point. Most importantly, viral set points were higher at time points long after IL-15 treatment had ceased, indicating that some other mechanism is at action.

Increased viral set points in IL-15 treated animals could be due to increased CD4+ T cell targets for infection. IL-15 can directly affect CD4+ T cells and macrophages, therefore increasing the target cell pool for SIV infection. The first studies describing the effect of IL-15 and IL-15Rα knockout mice concluded that CD4+ T cells are not affected in these mice (27, 58). This is in accordance with our study of IL-15 treated chronically SIV infected cynomolgus macaques where we have not observed any changes in activation, cell numbers and memory phenotype of blood CD4+ T (40). We and others have however observed that under certain circumstances, IL-15 can indeed act as co-stimulator albeit weak for memory CD4+ T cells (38, 5961). Furthermore, mitogen-activated human CD4+ T cells express the IL-15Rα chain (62) and IL-15-stimulated effector memory CD4+ T cells can migrate into tissue (38), suggesting that IL-15-responsive CD4+ T cells may migrate to sites of viral infection and replication. In the present study we did observed increased Ki-67 expression in CD4+ T cells at week 1 in IL-15 treated animals, however, this was not accompanied by increased peripheral blood CD4+ T cell numbers. This may indicate CD4+ T cells migration into tissue. We have not observed increased infected lymphocytes in inguinal lymph nodes or rectal biopsies in the acute infection. It is however possible that CD4+ T cells migrated into gut-associated lymphoid tissue (GALT), which was shown before to be one of the major site of viral replication (63). In week 30 LN, the absolute CD4+ T cell number is decreased, suggesting that CD4+ T cells in our animal model may be migrating preferentially into GALT and not LN. We found that CD45RA-CD62L− CD4+ T cells are diminished in the blood of IL-15 treated animals which suggests that these cells are either migrating into GALT or they are being consumed at sites of viral replication, since memory CD4+ T cells are the prime target for SIV infection. IL-15 treatment also reduced blood CCR5+ CD4+ T cells, something previously reported in chronic infection (63). Since IL-15 upregulates CCR5 on human CD4+ T cells (44, 64), the loss of blood CCR5+ CD4+ T cells suggests migration of these cells from peripheral blood into tissue and increased likelihood of infection with the CCR5-tropic SIVmac251 virus. This however remains to be determined. It is unlikely that monocytes, another target cell population for SIV infection, is the source of increased viral replication as the numbers and CCR5 expression of monocytes were not affected in IL-15 treated animals. That indeed activation and proliferation of CD4+ T cells early during acute SIV infection can alter the viral replication months later was further supported by the positive correlation we have found between percentage and absolute cell numbers of Ki-67+CD4+ T cells at day 7 and viral load at day 14 and day 84. Absolute numbers of HLA-DR+CD4+ T cells was also positively correlated with early (day 14) and late (day 84) viral replication. These findings suggest that viral replication during viral set point is already at least partially determined at day 7 by the magnitude of CD4+ T cell activation and proliferation.

Besides altering replication and target cell populations of SIV, changing the immune response against SIV could be another mechanism contributing to the disease acceleration and high viral loads induced by IL-15 treatment. The failure of NK cells and SIV-specific CD8+ T cells to control virus could result in the increased viral set point found in IL-15 treated animals. Although we only observed increases in blood SIV-specific CD8+ T cell numbers at week 2 in IL-15 treated animals, increased numbers of Gag-specific CD8+ T cells were found in lymph nodes even at week 30. Since numbers of blood HLA-DR+ Gag-specific CD8+ T cells were reduced in IL-15 treated monkeys, this may suggest migration of activated cells into tissues. The fact that viral replication is higher in IL-15 treated animals despite having more SIV-specific CD8+ T cells in the lymph nodes suggests that these cells may be either functionally defective or die there. If activated virus-specific CD8+ T cells accumulate at sites of viral replication, bystander killing or functional defects could be enhanced especially if viral replication is high. Further studies are necessary to determine whether SIV-specific CD8+ T cells in lymph nodes and possibly other sites are fully functional or exhausted effector CD8+ T cells.

IL-15 treatment did reduce significantly the numbers of blood NK cells without increasing them in lymph nodes. This may suggest an impairment of NK cells to control viral replication. On the other hand, it could suggest that the homeostasis of NK cells has been affected with possibly higher turnover of these cells as a result of higher viral replication in the IL-15 treated animals. It should be stressed that for both reduced activated SIV-specific CD8+ T cells and NK cells and the accompanied increased viral loads, two alternative explanations can be given. Either loss of activated SIV-specific CD8+ T cells and NK cells is resulting in reduced control of viral replication and hence increased viral set points in IL-15 treated animals, or alternatively, increased viral replication due to non-immunological mechanisms such as increased seeding of target cells results in exhaustion of activated SIV-specific CD8+ T cells and NK cells and thus the reduced numbers.

We also observed a decrease in anti-SIV antibodies in IL-15 treated compared to untreated animals. However, no concurrent decrease in B cell numbers in peripheral blood and LN was observed. More studies are necessary to examine more carefully the effect of IL-15 on B cell function. The decreased anti-SIV antibodies could indeed influence the outcome of SIV infection, as it was shown before that during progression to HIV and SIV, antibodies specific for HIV and SIV decrease or are absent (65, 66). We observed an inverse correlation between the amount of anti-SIV antibodies and viral replication at week 16. However, no correlation of anti-SIV antibodies at week 3 and viral replication at week 3 was observed, indicating that although anti-SIV antibodies are already significantly decreased early in SIV infection this does not associate with viral set point.

Although IL-15 treatment induced a 2–3 fold increase in SIV-specific CD8+ T cells during acute infection, it was rather surprising that this had no effect on peak viremia. IL-15 could be enhancing the proliferation or survival of these cells. IL-15 inhibits CD95-induced apoptosis of HIV-specific CD8+ T cells (34, 60) and in vivo IL-15 induces massive expansion of CD8+ T cells (40). Given that SIV-specific CD8+ T cells are already more than 90% Ki-67+ as we show, it is unlikely that IL-15 is augmenting their proliferation, most likely we are inhibiting the death of these cells. The fact that IL-15 increased SIV-specific CD8+ T cells and NK cells by 2–3 fold without any impact on peak viremia indicates how potent an immune response induced by an effective vaccine may need to be in order to impact on viral replication during acute infection.

IL-15 not only increased the viral set point but also led to accelerated disease progression to simian AIDS in 2 out of the 6 treated animals. In one of the two animals, histology revealed that the brain was affected in this animal. Neuropathologically, SIV infected macaques are known to reveal four distinct lesion profiles: minimal changes, early encephalitis, leukoencephalopathy and encephalitis (42). Detailed morphological evaluation of one animal that died of AIDS in our study revealed evidence of minimal changes and incipient early encephalitis in the form of rare mononuclear inflammatory cell infiltrates in the cerebral and cerebellar, in conjunction with rare microglial nodules in the subpial portions of the cerebral cortex. The overall paucity of meningeal and parenchymal infiltrates coupled by the lack of multinucleated giant cells, substantial cortical and subcortical presence of microglial nodules and/or myelin pallor in the cerebral hemispheric white matter argue against the diagnosis of a full-blown SIV encephalitis or leukoencephalopathy. Our findings suggest that this animal suffered from early minimal CNS SIV-associated disease and incipient early encephalitis. It should be noted that previous studies to date have failed to establish a relationship between neuropathological findings, numbers of SIV replicating cells, T cell infiltration and repertoires of pro-inflammatory cytokines (42). A recent study however suggests that IL-15 mRNA levels in the brain are increased in SIV infection and that this may indeed lead to maintenance of SIV-specific CD8+ T cells in the CNS (67). Our results could therefore be interpreted in different ways. Either IL-15 treatment increased the numbers of activated CD8+ T cells that could enter the brain and may therefore induce cytotoxic damage and inflammatory pathology. Or more SIV-infected cells could enter the brain in the IL-15 treated animals and promote brain pathology. Furthermore, as mentioned above, we found much lower anti-SIV antibodies in IL-15 treated animals compared to untreated animals. In a study using SIV/Delta–induced immunodeficiency disease CNS involvement was observed in animals which did not mount a good antibody response to the virus (68). This could indicate that the significant lower amount of anti-SIV antibodies found in the IL-15 treated animals at week 3 and 16 may be involved in the CNS damage we have observed. A strong anti-SIV response was also found in the plasma and cerebrospinal fluid of slow progressors but not of fast progressors when rhesus macaques were infected with SIVmac251 (69). Detailed studies will be necessary to reveal the mechanism responsible for this early involvement of the CNS in IL-15 treated animals and whether antibody levels play a part in this.

In summary, we have shown here that IL-15 treatment for 4 weeks during acute SIV infection of rhesus macaques increased the viral set point in all animals and accelerated disease progression to simian AIDS in 2 out of 6 animals with one of the animals developing SIV meningoencephalitis. Although 2–3 fold more SIV-specific CD8+ T cells and NK cells were observed in IL-15 treated animals this had no impact on peak viremia although numbers of infected cell in LN biopsies were reduced. Whereas activated SIV-specific CD8+ T cells and NK cells were reduced in the blood of IL-15 treated animals at viral set point, SIV-specific CD8+ T cells were increased in LN while NK cell numbers did not differ with IL-15 treatment. Early activation of CD4+ T cells followed by reduction of blood CCR5+ and CD45RA-CD62L− CD4+ T cells with IL-15 treatment suggest an increased use of these cells as targets of infection that leads to increased viral set point and infected cells in LN. The positive correlation between day 7 Ki-67+CD4+ and HLA-DR+CD4+ T cells and viral replication at day 84 further supports a direct association between early CD4+ T cell activation and viral set point. Finally, this study suggests that IL-15 treatment of acutely SIV-infected non-human primates may serve as a useful model to understand what controls viral set point in HIV infection.

Acknowledgement

We thank Louise Bertrand, Department of Neurobiology and Anatomy, Drexel University College of Medicine for assisting with figure preparations. We thank the NCRR funded Resource for Nonhuman Primate Immune Reagents for the recombinant rhesus macaque IL-15.

This study was supported by grants NIH R01 AI46719, AI52005 and AI62437 to PDK.

Abbreviations

LN
lymph nodes

References

1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–6110. [PMC free article] [PubMed]
2. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991–998. [PMC free article] [PubMed]
3. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–4655. [PMC free article] [PubMed]
4. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103–2106. [PubMed]
5. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857–860. [PubMed]
6. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, Forster R, Rowland-Jones S, Sekaly RP, McMichael AJ, Pantaleo G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature. 2001;410:106–111. [PubMed]
7. Mueller YM, De Rosa SC, Hutton JA, Witek J, Roederer M, Altman JD, Katsikis PD. Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells. Immunity. 2001;15:871–882. [PubMed]
8. Mueller YM, Petrovas C, Do DH, Altork SR, Fischer-Smith T, Rappaport J, Altman JD, Lewis MG, Katsikis PD. Early establishment and antigen dependence of SIV-specific CD8+ T cell defects. J Virol. 2007 [PMC free article] [PubMed]
9. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol. 1996;156:735–741. [PubMed]
10. Kennedy MK, Park LS. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J Clin Immunol. 1996;16:134–143. [PubMed]
11. Jonuleit H, Wiedemann K, Muller G, Degwert J, Hoppe U, Knop J, Enk AH. Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells: a role for IL-15 in attraction of T cells. J Immunol. 1997;158:2610–2615. [PubMed]
12. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264:965–968. [PubMed]
13. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, DuBose R, Cosman D, Park LS, Anderson DM. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. Embo J. 1995;14:3654–3663. [PMC free article] [PubMed]
14. Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997;99:937–943. [PMC free article] [PubMed]
15. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med. 2004;200:825–834. [PMC free article] [PubMed]
16. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17:537–547. [PubMed]
17. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin. Immunity. 2007;15 [PMC free article] [PubMed]
18. Berard M, Brandt K, Bulfone-Paus S, Tough DF. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol. 2003;170:5018–5026. [PubMed]
19. Chehimi J, Marshall JD, Salvucci O, Frank I, Chehimi S, Kawecki S, Bacheller D, Rifat S, Chouaib S. IL-15 enhances immune functions during HIV infection. J Immunol. 1997;158:5978–5987. [PubMed]
20. Dunne J, Lynch S, O'Farrelly C, Todryk S, Hegarty JE, Feighery C, Doherty DG. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol. 2001;167:3129–3138. [PubMed]
21. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A. 2000;97:11445–11450. [PMC free article] [PubMed]
22. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14–32. [PubMed]
23. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 2000;288:675–678. [PubMed]
24. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 2001;14:105–110. [PubMed]
25. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8:591–599. [PubMed]
26. Arnoult D, Petit F, Lelievre JD, Lecossier D, Hance A, Monceaux V, Hurtrel B, Ho Tsong Fang R, Ameisen JC, Estaquier J. Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ. 2003;10:1240–1252. [PubMed]
27. Lodolce JP, Boone DL, Chai S, Swain RE, Dassopoulos T, Trettin S, Ma A. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669–676. [PubMed]
28. Wilkinson PC, Liew FY. Chemoattraction of human blood T lymphocytes by interleukin-15. J Exp Med. 1995;181:1255–1259. [PMC free article] [PubMed]
29. Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood. 1997;90:2804–2809. [PubMed]
30. Umemura M, Nishimura H, Yajima T, Wajjwalk W, Matsuguchi T, Takahashi M, Nishiyama Y, Makino M, Nagai Y, Yoshikai Y. Overexpression of interleukin-15 prevents the development of murine retrovirus-induced acquired immunodeficiency syndrome. Faseb J. 2002;16:1755–1763. [PubMed]
31. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A. 2003;100:3392–3397. [PMC free article] [PubMed]
32. Bolesta E, Kowalczyk A, Wierzbicki A, Eppolito C, Kaneko Y, Takiguchi M, Stamatatos L, Shrikant PA, Kozbor D. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol. 2006;177:177–191. [PMC free article] [PubMed]
33. Xin KQ, Hamajima K, Sasaki S, Tsuji T, Watabe S, Okada E, Okuda K. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine. 1999;17:858–866. [PubMed]
34. Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, Altman JD, Katsikis PD. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood. 2003;101:1024–1029. [PubMed]
35. Petrovas C, Mueller YM, Dimitriou ID, Bojczuk PM, Mounzer KC, Witek J, Altman JD, Katsikis PD. HIV-specific CD8+ T cells exhibit markedly reduced levels of Bcl-2 and Bcl-xL. J Immunol. 2004;172:4444–4453. [PubMed]
36. Chitnis V, Pahwa R, Pahwa S. Determinants of HIV-specific CD8 T-cell responses in HIV-infected pediatric patients and enhancement of HIV-gag-specific responses with exogenous IL-15. Clin Immunol. 2003;107:36–45. [PubMed]
37. Kanai T, Thomas EK, Yasutomi Y, Letvin NL. IL-15 stimulates the expansion of AIDS virus-specific CTL. J Immunol. 1996;157:3681–3687. [PubMed]
38. Picker LJ, Reed-Inderbitzin EF, Hagen SI, Edgar JB, Hansen SG, Legasse A, Planer S, Piatak M, Jr., Lifson JD, Maino VC, Axthelm MK, Villinger F. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest. 2006;116:1514–1524. [PMC free article] [PubMed]
39. Suryanarayana K, Wiltrout TA, Vasquez GM, Hirsch VM, Lifson JD. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses. 1998;14:183–189. [PubMed]
40. Mueller YM, Petrovas C, Bojczuk PM, Dimitriou ID, Beer B, Silvera P, Villinger F, Cairns JS, Gracely EJ, Lewis MG, Katsikis PD. Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques. J Virol. 2005;79:4877–4885. [PMC free article] [PubMed]
41. Allen TM, Sidney J, del Guercio MF, Glickman RL, Lensmeyer GL, Wiebe DA, DeMars R, Pauza CD, Johnson RP, Sette A, Watkins DI. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol. 1998;160:6062–6071. [PubMed]
42. Boche D, Khatissian E, Gray F, Falanga P, Montagnier L, Hurtrel B. Viral load and neuropathology in the SIV model. Journal of neurovirology. 1999;5:232–240. [PubMed]
43. Hirsch VM, Dapolito G, Johnson PR, Elkins WR, London WT, Montali RJ, Goldstein S, Brown C. Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol. 1995;69:955–967. [PMC free article] [PubMed]
44. Perera LP, Goldman CK, Waldmann TA. IL-15 induces the expression of chemokines and their receptors in T lymphocytes. J Immunol. 1999;162:2606–2612. [PubMed]
45. Mothe BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, Allison DB, Watkins DI. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol. 2003;77:2736–2740. [PMC free article] [PubMed]
46. Zhang ZQ, Fu TM, Casimiro DR, Davies ME, Liang X, Schleif WA, Handt L, Tussey L, Chen M, Tang A, Wilson KA, Trigona WL, Freed DC, Tan CY, Horton M, Emini EA, Shiver JW. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol. 2002;76:12845–12854. [PMC free article] [PubMed]
47. Beq S, Nugeyre MT, Ho Tsong Fang R, Gautier D, Legrand R, Schmitt N, Estaquier J, Barre-Sinoussi F, Hurtrel B, Cheynier R, Israel N. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J Immunol. 2006;176:914–922. [PubMed]
48. Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, Hecht TT, Hill BJ, Komschlies K, Tomaszewski J, Franchini G, Mackall CL. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood. 2003;101:2294–2299. [PubMed]
49. Ansari AA, Mayne AE, Sundstrom JB, Bostik P, Grimm B, Altman JD, Villinger F. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J Virol. 2002;76:1731–1743. [PMC free article] [PubMed]
50. Craiu A, Barouch DH, Zheng XX, Kuroda MJ, Schmitz JE, Lifton MA, Steenbeke TD, Nickerson CE, Beaudry K, Frost JD, Reimann KA, Strom TB, Letvin NL. An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. AIDS Res Hum Retroviruses. 2001;17:873–886. [PubMed]
51. Villinger F, Miller R, Mori K, Mayne AE, Bostik P, Sundstrom JB, Sugimoto C, Ansari AA. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine. 2004;22:3510–3521. [PubMed]
52. Patki AH, Quinones-Mateu ME, Dorazio D, Yen-Lieberman B, Boom WH, Thomas EK, Lederman MM. Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression. J Clin Invest. 1996;98:616–621. [PMC free article] [PubMed]
53. Lucey DR, Pinto LA, Bethke FR, Rusnak J, Melcher GP, Hashemi FN, Landay AL, Kessler HA, Paxton RJ, Grabstein K, Shearer GM. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 1997;4:43–48. [PMC free article] [PubMed]
54. d'Ettorre G, Forcina G, Lichtner M, Mengoni F, D'Agostino C, Massetti AP, Mastroianni CM, Vullo V. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients. Aids. 2002;16:181–188. [PubMed]
55. Bayard-McNeeley M, Doo H, He S, Hafner A, Johnson WD, Jr., Ho JL. Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro. Clin Diagn Lab Immunol. 1996;3:547–553. [PMC free article] [PubMed]
56. Al-Harthi L, Roebuck KA, Landay A. Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production. J Clin Immunol. 1998;18:124–131. [PubMed]
57. Graziosi C, Gantt KR, Vaccarezza M, Demarest JF, Daucher M, Saag MS, Shaw GM, Quinn TC, Cohen OJ, Welbon CC, Pantaleo G, Fauci AS. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A. 1996;93:4386–4391. [PMC free article] [PubMed]
58. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon JJ. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771–780. [PMC free article] [PubMed]
59. Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood. 1996;88:230–235. [PubMed]
60. Mueller YM, Makar V, Bojczuk PM, Witek J, Katsikis PD. IL-15 enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and CD8+ effector-memory T cells. Int Immunol. 2003;15:49–58. [PubMed]
61. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med. 2001;194:1711–1719. [PMC free article] [PubMed]
62. Chae DW, Nosaka Y, Strom TB, Maslinski W. Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression. J Immunol. 1996;157:2813–2819. [PubMed]
63. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427–431. [PubMed]
64. Unutmaz D, Xiang W, Sunshine MJ, Campbell J, Butcher E, Littman DR. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J Immunol. 2000;165:3284–3292. [PubMed]
65. Hirsch VM, Santra S, Goldstein S, Plishka R, Buckler-White A, Seth A, Ourmanov I, Brown CR, Engle R, Montefiori D, Glowczwskie J, Kunstman K, Wolinsky S, Letvin NL. Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol. 2004;78:275–284. [PMC free article] [PubMed]
66. Nicholson JK, Spira TJ, Aloisio CH, Jones BM, Kennedy MS, Holman RC, McDougal JS. Serial determinations of HIV-1 titers in HIV-infected homosexual men: association of rising titers with CD4 T cell depletion and progression to AIDS. AIDS Res Hum Retroviruses. 1989;5:205–215. [PubMed]
67. Marcondes MC, Burdo TH, Sopper S, Huitron-Resendiz S, Lanigan C, Watry D, Flynn C, Zandonatti M, Fox HS. Enrichment and persistence of virus-specific CTL in the brain of simian immunodeficiency virus-infected monkeys is associated with a unique cytokine environment. J Immunol. 2007;178:5812–5819. [PubMed]
68. Zhang JY, Martin LN, Watson EA, Montelaro RC, West M, Epstein L, Murphey-Corb M. Simian immunodeficiency virus/delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia. J Infect Dis. 1988;158:1277–1286. [PubMed]
69. Sopper S, Sauer U, Hemm S, Demuth M, Muller J, Stahl-Hennig C, Hunsmann G, ter Meulen V, Dorries R. Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques. J Virol. 1998;72:9940–9947. [PMC free article] [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...